Showing 3781-3790 of 5773 results for "".
- MacuLogix Reaches Milestone with One Million Dark Adaptation Testshttps://modernod.com/news/maculogix-reaches-milestone-with-one-million-dark-adaptation-tests/2480853/MacuLogix announced that more than 1 million dark adaptation tests have been performed using either the company’s original AdaptDx or the head-mounted AdaptDx Pro guided by Theia. Both devices use the same proprietary technology to efficiently measure dark adaptatio
- iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerlandhttps://modernod.com/news/istar-medical-expands-commercial-rollout-with-first-miniject-surgeries-in-switzerland/2480852/iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angl
- Kala Pharmaceuticals Launches Its First Direct-to-Consumer Campaign to Increase Awareness of Dry Eye Flareshttps://modernod.com/news/kala-pharmaceuticals-launches-its-first-direct-to-consumer-campaign-to-increase-awareness-of-dry-eye-flares/2480850/Kala Pharmaceuticals, Inc. today announced the launch of its first direct-to-consumer (DTC) campaign, “There for the Flare.” The campaign leverages digital channels to educate patients about dry eye flares and EYSUVIS® (loteprednol etabonate ophthalmic suspension 0.25%) and encour
- Opthea Data for OPT-302 in Combination With Ranibizumab for PCV Presented at ARVOhttps://modernod.com/news/opthea-data-for-opt-302-in-combination-with-ranibizumab-for-pcv-presented-at-arvo-2022/2480848/Opthea announced that clinical data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The presentation, titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy,” was held
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- Aldeyra Therapeutics to Present at MOD Live! 2022 Meetinghttps://modernod.com/news/aldeyra-therapeutics-to-present-at-mod-live-2022-meeting/2480843/Aldeyra Therapeutics announced that Kelly Mizer, Aldeyra’s Vice President, Commercial Strategy and Operations, will present at the MOD Live! 2022 meeting, which will take place in Nashville, Tennessee, May 5–7, 2022. MOD Live! 2022 is an interactive educational program
- Zeiss Offers New SLT Application for the Visulas Green Therapeutic Laserhttps://modernod.com/news/zeiss-offers-new-slt-application-for-the-visulas-green-therapeutic-laser/2480842/Zeiss Medical Technology announced that it now offers the new SLT add-on to its Visulas green laser, part of an integrated glaucoma workflow designed to advance safe and effective glaucoma treatment. The new SLT laser feature offers unique protocols that may im
- The Vision Council Scholarship Fund Expands Within the National Federation of Opticianry Schools; Launches Grassroots Marketing Effort to Reach Studentshttps://modernod.com/news/the-vision-council-scholarship-fund-expands-within-the-national-federation-of-opticianry-schools-launches-grassroots-marketing-effort-to-reach-students/2480840/The Vision Council announced that it is expanding the
- J&J Vision Presents New Data on Myopia, IOLs, Phacoemulsification, Dry Eye Drops, Vision Science and Refractive Technologieshttps://modernod.com/news/jj-vision-presents-new-data-on-myopia-iols-phacoemulsification-dry-eye-drops-vision-science-and-refractive-technologies-at-arvo/2480839/Johnson & Johnson Vision is presenting 26 poster and podium presentations focusing on myopia, cataract, dry eye, vision science, and refractive research at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Live and Virtual Annual Meeting. Johnson & Johnson Vision poster
- Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03https://modernod.com/news/bausch-lomb-presents-data-from-second-pivotal-phase-3-trial-of-investigational-treatment-nov03-at-arvo/2480837/Bausch + Lomb and Novaliq announced that data from the second pivotal phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-c